Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02762266 | Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization | terminated | Phase 3 | 13 | Stanford UniversityOTHER | 2 | Mar 12, 2024 | clinicaltrials |
| NCT05121948 | A Study of HC-7366 to Establish the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) | terminated | Phase 1 | 35 | HiberCell, Inc.INDUSTRY | 1 | Mar 8, 2024 |
| clinicaltrials |
| NCT03709082 | Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | terminated | Phase 1 / Phase 2 | 3 | University of Kansas Medical CenterOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT00019695 | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03878524 | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial | terminated | Phase 1 | 2 | OHSU Knight Cancer InstituteOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03812562 | Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection | terminated | Early Phase 1 | 2 | Northwestern UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03345784 | Testing AZD1775 inC Combination With Radiotherapy and Chemotherapy in Cervical, Upper Vaginal and Uterine Cancers | terminated | Phase 1 | 10 | National Cancer Institute (NCI)NIH | 2 | Feb 20, 2024 | clinicaltrials |
| NCT03997448 | Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149 | terminated | Phase 2 | 3 | Nataliya UbohaOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT04461600 | A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer(TENACITY) | terminated | Phase 2 | 18 | Ayala Pharmaceuticals, Inc,INDUSTRY | 5 | Feb 12, 2024 | clinicaltrials |
| NCT03376659 | Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 8 | Georgetown UniversityOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT04025216 | A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers | terminated | Phase 1 | 16 | Kite, A Gilead CompanyINDUSTRY | 1 | Jan 24, 2024 | clinicaltrials |
| NCT03606486 | Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer | terminated | N/A | 52 | University of WashingtonOTHER | 1 | Jan 17, 2024 | clinicaltrials |
| NCT03422679 | Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies | terminated | Phase 1 / Phase 2 | 79 | Cellestia Biotech AGINDUSTRY | 6 | Jan 16, 2024 | clinicaltrials |
| NCT03992131 | A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR) | terminated | Phase 1 / Phase 2 | 25 | pharmaand GmbHINDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT03709771 | Novel Mechanisms and Predictors of VEGF Receptor Inhibitor- or Immune Checkpoint Inhibitor-Associated Hypertension and Cardiovascular Disease | terminated | — | 2 | Vanderbilt University Medical CenterOTHER | 1 | Jan 12, 2024 | clinicaltrials |
| NCT04046887 | Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) | terminated | Phase 1 | 14 | Patrick Joseph Loehrer Sr.OTHER | 1 | Jan 5, 2024 | clinicaltrials |
| NCT04244552 | A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | terminated | Phase 1 | 87 | Atreca, Inc.INDUSTRY | 1 | Dec 29, 2023 | clinicaltrials |
| NCT04187872 | LITT and Pembrolizumab in Recurrent Brain Metastasis(TORCH) | terminated | Phase 1 | 10 | University of FloridaOTHER | 1 | Dec 27, 2023 | clinicaltrials |
| NCT04341740 | Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma(WindMIL-001) | terminated | N/A | 6 | University of OklahomaOTHER | 1 | Dec 13, 2023 | clinicaltrials |
| NCT03525392 | Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1. | terminated | Phase 1 | 14 | IpsenINDUSTRY | 5 | Dec 12, 2023 | clinicaltrials |
| NCT02802124 | Carbon Ion Radiotherapy for the Treatment of Chinese Hepatocellular Carcinoma | terminated | N/A | 30 | Shanghai Proton and Heavy Ion CenterOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT05184283 | Utilization of MAsS in Patients Undergoing LT for HCC | terminated | — | 11 | Columbia UniversityOTHER | 1 | Dec 7, 2023 | clinicaltrials |
| NCT01897454 | Gemcitabine Hydrochloride, and Radiation Therapy in Patients With Borderline Resectable Pancreatic Cancer | terminated | Phase 2 | 23 | Albert Einstein College of MedicineOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT04690855 | A Study to Evaluate TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast Cancer(TARA) | terminated | Phase 2 | 1 | Mylin A. Torres, MDOTHER | 1 | Dec 4, 2023 | clinicaltrials |
| NCT03861403 | A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors | terminated | Phase 1 | 10 | Leap Therapeutics, Inc.INDUSTRY | 1 | Nov 30, 2023 | clinicaltrials |
| NCT03641287 | The Effects of Exercise on Distress, Quality of Life, and Biomarkers in Ovarian Cancer Survivors | terminated | N/A | 64 | University of WashingtonOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT03867370 | Toripalimab in Combination With Lenvatinib as Neoadjuvant Therapy in Resectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 40 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT02963363 | Adapted Physical Activity for Breast Cancer HER2 Positive Patient(APACAN2) | terminated | N/A | 36 | Centre Jean PerrinOTHER | 1 | Nov 24, 2023 | clinicaltrials |
| NCT01690715 | Prognostic Value Related to the Presence of Thrombosis or Portal Vein Invasion in Patients With Hepatocellular Carcinoma Submitted to Surgery(HSL2012-06) | terminated | — | 50 | Hospital Sirio-LibanesOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT04329949 | Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma(RELIANT) | terminated | Phase 3 | 43 | Corcept TherapeuticsINDUSTRY | 1 | Nov 18, 2023 | clinicaltrials |
| NCT04565327 | Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 7 | Zhen Wang, MDOTHER | 1 | Nov 13, 2023 | clinicaltrials |
| NCT02127073 | Pilot Study of Oxytocin and microRNA Identification in NAF, Serum, and Tissue in Women With Breast Cancer | terminated | Phase 2 | 8 | Montefiore Medical CenterOTHER | 1 | Nov 9, 2023 | clinicaltrials |
| NCT01849874 | A Study of MEK162 vs. Physician's Choice Chemotherapy in Patients With Low-grade Serous Ovarian, Fallopian Tube or Peritoneal Cancer | terminated | Phase 3 | 341 | PfizerINDUSTRY | 19 | Oct 30, 2023 | clinicaltrials |
| NCT04300140 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 72 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT04983407 | Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma | terminated | Phase 1 / Phase 2 | 34 | Aravive, Inc.INDUSTRY | 1 | Oct 30, 2023 | clinicaltrials |
| NCT01041027 | Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Endometrial Cancer | terminated | Phase 2 | 31 | Albert Einstein College of MedicineOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT01307956 | Panitumumab, Combination Chemotherapy, & Radiation Therapy in Esophageal or Gastroesophageal Junction Cancer | terminated | Phase 2 | 11 | University of NebraskaOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT03649841 | Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer | terminated | Phase 2 | 10 | University of WashingtonOTHER | 1 | Oct 26, 2023 | clinicaltrials |
| NCT05329545 | Upifitamab Rilsodotin Maintenance in Platinum-Sensitive Recurrent Ovarian Cancer (UP-NEXT)(UP-NEXT) | terminated | Phase 3 | 20 | Mersana TherapeuticsINDUSTRY | 3 | Oct 26, 2023 | clinicaltrials |
| NCT04235660 | Y90 Radiation Segmentectomy vs SBRT for HCC(SBRT vs Y90) | terminated | N/A | 2 | Indiana UniversityOTHER | 1 | Oct 25, 2023 | clinicaltrials |
| NCT02383433 | Regorafenib Plus Gemcitabine in Metastatic Pancreatic Cancer | terminated | Phase 2 | 2 | Case Comprehensive Cancer CenterOTHER | 1 | Oct 23, 2023 | clinicaltrials |
| NCT04977401 | EndoscoPic Submucosal dIssection Using geL Versus glycerOl for Submucosal iNjection(EPSILON) | terminated | N/A | 32 | Erasme University HospitalOTHER | 3 | Oct 23, 2023 | clinicaltrials |
| NCT03592641 | Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 17, 2023 | clinicaltrials |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas(REGIRI) | terminated | Phase 1 / Phase 2 | 89 | UNICANCEROTHER | 1 | Oct 16, 2023 | clinicaltrials |
| NCT03490760 | Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas | terminated | Phase 2 | 9 | Baptist Health South FloridaOTHER | 1 | Oct 12, 2023 | clinicaltrials |
| NCT02847468 | Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib(PREMETHEP) | terminated | N/A | 61 | Centre Georges Francois LeclercOTHER | 1 | Oct 11, 2023 | clinicaltrials |
| NCT01873833 | Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer | terminated | Phase 2 | 10 | University of Southern CaliforniaOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT04428437 | Safety and Efficacy of Lenvatinib in Subjects With HCC Progression After First Line Treatment With Checkpoint Inhibitors | terminated | — | 17 | Humanity & Health Medical Group LimitedOTHER | 1 | Oct 5, 2023 | clinicaltrials |
| NCT04139993 | RBX7455 Before Surgery for the Treatment of Operable Breast Cancer | terminated | Phase 1 | 3 | Mayo ClinicOTHER | 1 | Oct 4, 2023 | clinicaltrials |
| NCT04203901 | Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma | terminated | Phase 2 | 16 | CoImmuneINDUSTRY | 1 | Oct 2, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Mar 12, 2024source: clinicaltrials